{
  "$schema": "https://github.com/Open-Systems-Pharmacology/QualificationPlan/releases/download/v1.0/OSP_Qualification_Plan_Schema.json",
  "Projects": [
    {
      "Id": "Raltegravir",
      "Path": "https://raw.githubusercontent.com/Incei/Raltegravir-Model/master/Raltegravir.json",
      "BuildingBlocks": []
    },
    {
      "Id": "Atazanavir",
      "Path": "https://raw.githubusercontent.com/Incei/Atazanavir-Model/master/Atazanavir.json",
      "BuildingBlocks": []
    },
    {
      "Id": "Atazanavir-Raltegravir-DDI",
      "Path": "https://raw.githubusercontent.com/Incei/Atazanavir-Raltegravir-DDI/master/Atazanavir-Raltegravir-DDI.json",
      "BuildingBlocks": [
        {
          "Type": "Compound",
          "Name": "Raltegravir",
          "Project": "Raltegravir"
        },
        {
          "Type": "Compound",
          "Name": "Atazanavir",
          "Project": "Atazanavir"
        },
        {
          "Type": "Formulation",
          "Name": "Reyataz capsule",
          "Project": "Atazanavir"
        },
        {
          "Type": "Formulation",
          "Name": "filmcoated tablet (original Merck formulation)",
          "Project": "Raltegravir"
        }
      ]
    }
  ],
  "ObservedDataSets": [
    {
      "Id": "DDI Ratios",
      "Path": "https://raw.githubusercontent.com/sfrechen/Database-for-observed-data/master/DDI.csv",
      "Type": "DDIRatio"
    }
  ],
  "Plots": {
    "PlotSettings": {
      "ChartWidth": 500,
      "ChartHeight": 400,
      "Fonts": {
        "AxisSize": 11,
        "LegendSize": 9,
        "OriginSize": 9,
        "FontFamilyName": "Arial",
        "WatermarkSize": 40
      }
    },
    "AxesSettings": {
      "ComparisonTimeProfile": [
        {
          "Unit": "h",
          "Dimension": "Time",
          "Type": "X",
          "GridLines": false,
          "Scaling": "Linear"
        },
        {
          "Unit": "ng/ml",
          "Dimension": "Concentration (mass)",
          "Type": "Y",
          "GridLines": false,
          "Scaling": "Log"
        }
      ],
      "DDIRatioPlotsPredictedVsObserved": [
        {
          "Unit": "",
          "Dimension": "Dimensionless",
          "Type": "X",
          "GridLines": false,
          "Scaling": "Log"
        },
        {
          "Unit": "",
          "Dimension": "Dimensionless",
          "Type": "Y",
          "GridLines": false,
          "Scaling": "Log"
        }
      ],
      "DDIRatioPlotsResidualsVsObserved": [
        {
          "Unit": "",
          "Dimension": "Dimensionless",
          "Type": "X",
          "GridLines": false,
          "Scaling": "Log"
        },
        {
          "Unit": "",
          "Dimension": "Dimensionless",
          "Type": "Y",
          "GridLines": false,
          "Scaling": "Log"
        }
      ]
    },
    "ComparisonTimeProfilePlots": [
      {
        "SectionId": 26,
        "Title": "Iwamoto 2008",
        "SimulationDuration": 176,
        "TimeUnit": "h",
        "OutputMappings": [
          {
            "Project": "Atazanavir-Raltegravir-DDI",
            "Simulation": "Iwamoto2008_Raltegravir",
            "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
            "ObservedData": "Iwamoto 2008 - Study I, Period 1 (single oral dose of 100 mg raltegravir) - Raltegravir - PO - 100 mg - Plasma - agg. (n=10)",
            "StartTime": 0,
            "TimeUnit": "h",
            "Color": "#2166ac",
            "Caption": "Control (without atazanavir)",
            "Symbol": "Circle"
          },
          {
            "Project": "Atazanavir-Raltegravir-DDI",
            "Simulation": "Iwamoto2008_Raltegravir+Atazanavir",
            "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
            "ObservedData": "Iwamoto 2008 - Study I, Period 2 (single oral dose of 100 mg raltegravir with multiple doses of 400 mg atazanavir) - Raltegravir - PO - 100 mg - Plasma - agg. (n=10)",
            "StartTime": 144,
            "TimeUnit": "h",
            "Color": "#b2182b",
            "Caption": "Treatment (with atazanavir)",
            "Symbol": "Square"
          }
        ]
      },
      {
        "SectionId": 26,
        "Title": "Krishna 2016",
        "SimulationDuration": 216,
        "TimeUnit": "h",
        "OutputMappings": [
          {
            "Project": "Atazanavir-Raltegravir-DDI",
            "Simulation": "Krishna2016_Raltegravir",
            "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
            "ObservedData": "Krishna 2016 - Period 1, Day 1 (single oral dose of 1200 mg raltegravir) - Raltegravir - PO - 1200 mg - Plasma - agg. (n=14)",
            "StartTime": 0,
            "TimeUnit": "h",
            "Color": "#2166ac",
            "Caption": "Control (without atazanavir)",
            "Symbol": "Circle"
          },
          {
            "Project": "Atazanavir-Raltegravir-DDI",
            "Simulation": "Krishna2016_Raltegravir+Atazanavir",
            "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
            "ObservedData": "Krishna 2016 - Period 2, Day 7 (single oral dose of 1200 mg raltegravir with multiple oral QD doses of 400 mg atazanavir) - Raltegravir - PO - 1200 mg - Plasma - agg. (n=12)",
            "StartTime": 144,
            "TimeUnit": "h",
            "Color": "#b2182b",
            "Caption": "Treatment (with atazanavir)",
            "Symbol": "Square"
          }
        ]
      },
      {
        "SectionId": 26,
        "Title": "Neely 2010",
        "SimulationDuration": 192,
        "TimeUnit": "h",
        "OutputMappings": [
          {
            "Project": "Atazanavir-Raltegravir-DDI",
            "Simulation": "Neely2010_Raltegravir",
            "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
            "ObservedData": "Neely 2010 - Study arm A (Raltegravir 400mg twice daily) - Raltegravir - PO - 400 mg - Plasma - agg. (n=20)",
            "StartTime": 168,
            "TimeUnit": "h",
            "Color": "#2166ac",
            "Caption": "Control (without atazanavir)",
            "Symbol": "Circle"
          },
          {
            "Project": "Atazanavir-Raltegravir-DDI",
            "Simulation": "Neely2010_Raltegravir+Atazanavir",
            "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
            "ObservedData": "Neely 2010 - Study arm B (Raltegravir 400mg + Atazanavir 400 mg once daily) - Raltegravir - PO - 400 mg - Plasma - agg. (n=19)",
            "StartTime": 168,
            "TimeUnit": "h",
            "Color": "#b2182b",
            "Caption": "Treatment (with atazanavir)",
            "Symbol": "Square"
          }
        ]
      },
      {
        "SectionId": 26,
        "Title": "Zhu 2010",
        "SimulationDuration": 612,
        "TimeUnit": "h",
        "OutputMappings": [
          {
            "Project": "Atazanavir-Raltegravir-DDI",
            "Simulation": "Zhu2010_Raltegravir",
            "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
            "ObservedData": "Zhu 2010 - Raltegravir 400 mg twice daily - Raltegravir - PO - 400 mg - Plasma - agg. (n=22)",
            "StartTime": 96,
            "TimeUnit": "h",
            "Color": "#2166ac",
            "Caption": "Control (without atazanavir)",
            "Symbol": "Circle"
          },
          {
            "Project": "Atazanavir-Raltegravir-DDI",
            "Simulation": "Zhu2010_Raltegravir+Atazanavir",
            "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
            "ObservedData": "Zhu 2010 - Raltegravir 400 mg twice daily plus atazanavir 300 mg twice daily - Raltegravir - PO - 400 mg - Plasma - agg. (n=19)",
            "StartTime": 600,
            "TimeUnit": "h",
            "Color": "#b2182b",
            "Caption": "Treatment (with atazanavir)",
            "Symbol": "Square"
          }
        ]
      }
    ],
    "DDIRatioPlots": [
      {
        "SectionId": 5,
        "Title": "UGT1A1 DDI",
        "PKParameter": "AUC|CMAX",
        "PlotType": "predictedVsObserved|residualsVsObserved",
        "Groups": [
          {
            "Caption": "Atazanavir + Raltegravir",
            "Color": "#FF0000",
            "Symbol": "Square",
            "DDIRatios": [
              {
                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                "ObservedData": "DDI Ratios",
                "ObservedDataRecordId": 571,
                "SimulationControl": {
                  "Project": "Atazanavir-Raltegravir-DDI",
                  "Simulation": "Iwamoto2008_Raltegravir",
                  "StartTime": 0,
                  "EndTime": 9999,
                  "TimeUnit": "h"
                },
                "SimulationDDI": {
                  "Project": "Atazanavir-Raltegravir-DDI",
                  "Simulation": "Iwamoto2008_Raltegravir+Atazanavir",
                  "StartTime": 144,
                  "EndTime": 9999,
                  "TimeUnit": "h"
                }
              },
              {
                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                "ObservedData": "DDI Ratios",
                "ObservedDataRecordId": 575,
                "SimulationControl": {
                  "Project": "Atazanavir-Raltegravir-DDI",
                  "Simulation": "Krishna2016_Raltegravir",
                  "StartTime": 0,
                  "EndTime": 9999,
                  "TimeUnit": "h"
                },
                "SimulationDDI": {
                  "Project": "Atazanavir-Raltegravir-DDI",
                  "Simulation": "Krishna2016_Raltegravir+Atazanavir",
                  "StartTime": 144,
                  "EndTime": 9999,
                  "TimeUnit": "h"
                }
              },
              {
                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                "ObservedData": "DDI Ratios",
                "ObservedDataRecordId": 573,
                "SimulationControl": {
                  "Project": "Atazanavir-Raltegravir-DDI",
                  "Simulation": "Neely2010_Raltegravir",
                  "StartTime": 168,
                  "EndTime": 180,
                  "TimeUnit": "h"
                },
                "SimulationDDI": {
                  "Project": "Atazanavir-Raltegravir-DDI",
                  "Simulation": "Neely2010_Raltegravir+Atazanavir",
                  "StartTime": 168,
                  "EndTime": 192,
                  "TimeUnit": "h"
                }
              },
              {
                "Output": "Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)",
                "ObservedData": "DDI Ratios",
                "ObservedDataRecordId": 579,
                "SimulationControl": {
                  "Project": "Atazanavir-Raltegravir-DDI",
                  "Simulation": "Zhu2010_Raltegravir",
                  "StartTime": 96,
                  "EndTime": 108,
                  "TimeUnit": "h"
                },
                "SimulationDDI": {
                  "Project": "Atazanavir-Raltegravir-DDI",
                  "Simulation": "Zhu2010_Raltegravir+Atazanavir",
                  "StartTime": 600,
                  "EndTime": 612,
                  "TimeUnit": "h"
                }
              }
            ]
          }
        ]
      }
    ]
  },
  "Inputs": [
    {
      "Project": "Raltegravir",
      "Name": "Raltegravir",
      "Type": "Compound",
      "SectionId": 11
    },
    {
      "Project": "Atazanavir",
      "Name": "Atazanavir",
      "Type": "Compound",
      "SectionId": 16
    },
    {
      "Project": "Raltegravir",
      "Name": "filmcoated tablet (original Merck formulation)",
      "Type": "Formulation",
      "SectionId": 16
    },
    {
      "Project": "Atazanavir",
      "Name": "Reyataz capsule",
      "Type": "Formulation",
      "SectionId": 16
    }
  ],
  "Sections": [
    {
      "Id": 1,
      "Title": "Introduction",
      "Content": "Content/Empty.md",
      "Sections": [
        {
          "Id": 2,
          "Title": "Objective",
          "Content": "Content/Empty.md"
        },
        {
          "Id": 3,
          "Title": "CYP3A4 DDI Network",
          "Content": "Content/Empty.md"
        },
        {
          "Id": 4,
          "Title": "Qualification Workflow",
          "Content": "Content/Empty.md"
        }
      ]
    },
    {
      "Id": 5,
      "Title": "Qualification of Use Case CYP3A4-mediated DDI",
      "Content": "Content/Empty.md"
    },
    {
      "Id": 6,
      "Title": "Appendix",
      "Content": "Content/Empty.md",
      "Sections": [
        {
          "Id": 7,
          "Title": "Open Systems Pharmacology Suite (OSPS) Introduction",
          "Content": "Content/Empty.md"
        },
        {
          "Id": 8,
          "Title": "Mathematical Implementation of drug-drug interactions",
          "Content": "Content/Empty.md"
        },
        {
          "Id": 9,
          "Title": "Evaluation of victim and perpetrator models",
          "Content": "Content/Empty.md",
          "Sections": [
            {
              "Id": 10,
              "Title": "Raltegravir model",
              "Content": "Content/Empty.md",
              "Sections": [
                {
                  "Id": 11,
                  "Title": "Input parameters",
                  "Content": "Content/Empty.md"
                },
                {
                  "Id": 12,
                  "Title": "Model evaluation",
                  "Content": "Content/Empty.md",
                  "Sections": [
                    {
                      "Id": 13,
                      "Title": "Concentration-time profiles",
                      "Content": "Content/Empty.md"
                    },
                    {
                      "Id": 14,
                      "Title": "Overall goodness of fit",
                      "Content": "Content/Empty.md"
                    }
                  ]
                }
              ]
            },
            {
              "Id": 15,
              "Title": "Atazanavir model",
              "Content": "Content/Empty.md",
              "Sections": [
                {
                  "Id": 16,
                  "Title": "Input parameters",
                  "Content": "Content/Empty.md"
                },
                {
                  "Id": 17,
                  "Title": "Model evaluation",
                  "Content": "Content/Empty.md",
                  "Sections": [
                    {
                      "Id": 18,
                      "Title": "Concentration-time profiles",
                      "Content": "Content/Empty.md"
                    },
                    {
                      "Id": 19,
                      "Title": "Overall goodness of fit",
                      "Content": "Content/Empty.md"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "Id": 25,
          "Title": "Evaluation of DDI network (coupled perpetrator / victim simulations)",
          "Content": "Content/Empty.md",
          "Sections": [
            {
              "Id": 26,
              "Title": "Atazanavir-raltegravir DDI",
              "Content": "Content/Empty.md"
            }
          ]
        }
      ]
    }
  ]
}